

Oziltus

India · access guide

Oziltus access in India: the CDSCO named-patient pathway

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in India access Oziltus (tislelizumab-jsgr) for adult patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours that have progressed following prior treatment and other FDA-approved indications including unresectable HCC, ESCC, and gastric/GEJ adenocarcinoma in approved combinations through the CDSCO named-patient pathway, a Central Drugs Standard Control Organisation-administered mechanism that allows a Indian-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in INR.

Why Indian patients need Oziltus through the named-patient pathway

The Republic of India operates a structured pharmaceutical regulatory environment. Oziltus (tislelizumab-jsgr) is regulated through CDSCO (Central Drugs Standard Control Organisation) channels, and a Indian family asking for Oziltus is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.

Four converging patterns drive these cases. First, indication lag. Oziltus's newer FDA-approved indications and dosing expansions often reach local registration 12 to 36 months after the US label. A family whose treating physician has documented a clear FDA-label fit may still find that the local label has not caught up. Second, presentation gaps. The exact strength, weight-banded dose, or pen format the prescriber needs may not be stocked at the local agent even when the medicine is registered. Third, payer denial. Star Health, HDFC ERGO, and ICICI Lombard each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register. Cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply. When a US-stable patient relocates to India or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.

In each pattern, the CDSCO named-patient pathway is the mechanism that connects a Indian-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient. Clinically, Oziltus is a humanised IgG4 anti-PD-1 monoclonal antibody engineered with a modified Fc region to minimise Fc-gamma-receptor binding on macrophages, theoretically preserving PD-1-positive T-cell activation, and the named-patient route preserves that mechanism rather than substituting a non-equivalent local option.

The CDSCO named-patient pathway for Oziltus

The pathway for an Indian-licensed physician to obtain a medicine that is not registered or not stocked locally is Rule 36 of the New Drugs and Clinical Trials Rules, 2019, which permits the personal import of a small quantity of an unregistered drug for the bona fide use of a named patient, supplemented by Form 12A institutional compassionate-use authorisation for hospital-administered therapies, with applications filed through the CDSCO SUGAM portal at cdscoonline.gov.in. The framework allows registered healthcare facilities to import a specific medicine for a specific patient when the medicine is approved by a recognised reference authority (typically the US FDA, EMA, MHRA, PMDA Japan, or Health Canada) and a clinically equivalent locally registered alternative is not suitable. For Oziltus specifically, the clinical justification typically frames the case around the precise FDA-approved indication and the documented gap in the local route.

A complete application includes a clinical justification letter from the treating physician (diagnosis, severity, prior therapies, why this specific drug, why the locally stocked option is not suitable for this case), the treating physician's Indian medical license verification through the State Medical Council and the CDSCO Zonal Office, an anonymised patient identifier where the CDSCO submission allows, full product details (brand name, generic name, manufacturer, strength, dosage form, pack size, quantity requested, intended treatment duration), the destination dispensing facility name, license number, and pharmacy in charge, and a chain-of-custody plan describing how the medicine will move from the US manufacturer through the importer to the dispensing pharmacy.

For Oziltus, the clinical justification angle typically rests on one or more of three documented elements: a pediatric or weight-banded request that fits the FDA label but not the local label, a denied biologic or specialty claim where prior step-therapy has been documented, or a continuity-of-supply request for a patient previously stabilised on the US-sourced presentation. The treating physician documents the relevant clinical criteria for the prescribed indication: severity scores, biomarker levels, prior therapy failures, and the rationale for Oziltus versus the next-in-line local alternative.

Approval timelines for routine cases are typically 10 to 30 business days. Complex cases (rare indication, larger quantities, first import of a given pediatric or weight-banded format) can extend to 6 to 10 weeks. CDSCO retains discretion on timing, and we do not promise specific durations.

Where Oziltus gets dispensed in India

A small group of Indian institutions handle named-patient imports as established workflow, with in-house import pharmacy infrastructure and physicians experienced with the application set. Tertiary and major private hospitals that meet this profile include Apollo Hospitals in Chennai, Hyderabad, and Delhi, Tata Memorial Hospital in Mumbai (for oncology) and AIIMS New Delhi (for rare disease), and Fortis Memorial Research Institute in Gurugram and Max Super Speciality Hospital Saket in Delhi. Each maintains pharmacy infrastructure appropriate to the storage requirements of the imported medicine (2 to 8 degrees Celsius cold-chain for biologics, ambient storage for oral therapies, ultra-cold or specialised handling where the FDA label requires it).

For physicians at smaller hospitals without internal import infrastructure, the common pattern is to route through a specialty importer that holds a pharmaceutical establishment license and files the CDSCO application on the prescribing physician's behalf. The medicine then moves into the prescribing hospital's outpatient or specialty pharmacy under chain-of-custody documentation.

Real cost picture for Oziltus in India

US WAC for Oziltus runs in the range of USD 151,800 to USD 178,200 per year at the standard FDA-labelled regimen for adult patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours that have progressed following prior treatment and other FDA-approved indications including unresectable HCC, ESCC, and gastric/GEJ adenocarcinoma in approved combinations. INR is trading at approximately 83.5 INR to 1 USD, so the annual reference range converts to roughly INR 12,675,000 to INR 14,880,000 for the drug itself at US WAC equivalents.

International logistics for shipment to India typically runs USD 250 to USD 900 depending on destination city, urgency, and presentation (cold-chain biologics carry the higher end of the range; ambient oral solids the lower). The Republic of India customs and CDSCO permit fees are nominal relative to drug cost. Reserve Meds' concierge fee is itemised separately on every firm quote.

On the insurance side, Star Health, HDFC ERGO, and ICICI Lombard each assess named-patient imports case by case. Some reimburse fully when the medicine is on their formulary even if not stocked, some reimburse a percentage subject to copay, and many require pre-authorization. We do not promise coverage from any insurer. US manufacturer copay cards and patient assistance programs do not extend internationally; cross-border patients pay cash or rely on local payer coverage.

Typical timeline for Oziltus in India

CDSCO routine processing is typically 10 to 30 business days from a complete filing. International logistics adds 2 to 5 additional days depending on whether the presentation is ambient or cold-chain, the dispensing city, and customs clearance. End-to-end, most routine adult cases complete within 3 to 6 weeks from first complete documentation. Pediatric, weight-banded, or first-import cases can run slightly longer because presentation selection and first-import scrutiny can extend CDSCO review.

For temperature-sensitive products, the dispensing facility must maintain validated storage with continuous monitoring; the manufacturer's room-temperature excursion runway on the FDA label informs how we plan the Gulf, South Asia, or North Africa shipping lane, and the cold chain is broken only at the dispensing pharmacy under documented control.

When a case is on a clinical clock (a flare, a new diagnosis with an active disease, or a treatment cycle scheduled at the dispensing centre), the practical question is which step controls the timeline. In our experience the binding step is rarely the CDSCO review itself when the application is filed clean; it is usually documentation completeness on the prescriber's side or, for cold-chain biologics, the dispensing facility's storage and monitoring confirmation. The intake is where we lock the case-team contact, gather the documents in parallel, and start the US sourcing clock so that approval and product land in the same week rather than serially.

What your physician needs to provide

For a Indian-licensed specialist prescribing Oziltus through the CDSCO pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's confirmed diagnosis for adult patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours that have progressed following prior treatment and other FDA-approved indications including unresectable HCC, ESCC, and gastric/GEJ adenocarcinoma in approved combinations, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate for the indication), prior therapy history including first-line options tried, and a clinical rationale for why Oziltus is the appropriate next step given a humanised IgG4 anti-PD-1 monoclonal antibody engineered with a modified Fc region to minimise Fc-gamma-receptor binding on macrophages, theoretically preserving PD-1-positive T-cell activation.

The letter also specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan should reference any baseline laboratory or imaging requirements specific to Oziltus (full blood count, liver function, infection screen, ophthalmology assessment, or pregnancy testing where the FDA label requires it), planned follow-up intervals, and dose-modification criteria for the most common adverse events.

The treating physician's Indian license number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record we share with the importer.

Common questions about Oziltus in India

Will Star Health, HDFC ERGO, and ICICI Lombard cover this? Each insurer assesses named-patient imports case by case. Some reimburse fully when Oziltus is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by CDSCO? The CDSCO named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; CDSCO review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine? Any Indian-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The State Medical Council and the CDSCO Zonal Office verifies the active license; the CDSCO application records both the prescribing physician and the dispensing facility.

Can I receive Oziltus at home? The dispensing facility must be Indian-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class? Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Where Reserve Meds fits in Oziltus cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace CDSCO, and we do not replace your dispensing pharmacy. For Oziltus specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into India, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Oziltus case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the CDSCO application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Indian tertiary specialty care concentrates at the Apollo, Tata Memorial, AIIMS, Max, and Fortis networks across Chennai, Hyderabad, Mumbai, Delhi, and Gurugram; the CDSCO Form 12A named-patient import authorisation is the standard mechanism for unregistered specialty medicines and is typically filed by the treating consultant at one of these centres.

Reserve Meds's role

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

Reserve Meds

reserved for you.

Composite case examples. This document is for general information only and does not constitute medical advice. Please consult your treating physician.

Reserve Meds is in pre-launch. Published timelines and cost ranges are indicative, not guarantees.

reservemeds.com · hello@reservemeds.com